DE-ROCKET.CHAT
22.7.2021 14:02:09 CEST | Business Wire | Press release
Rocket.Chat , the leading open-source communication hub, is announcing the release of Catalyst , its new partner program that consolidates all the assets needed to accelerate growth of new and existing partners across the globe.
“Since the beginning we have been working in close collaboration with service and technology providers to deliver increased value to our customers, which naturally led us to clearly understand the key aspects needed to support our partners’ growth throughout their journey and ultimately leverage their ROI through our partnership. Rocket.Chat’s Catalyst materializes these learnings into a journey-based program that will support companies of all sizes that target the same market and want to establish a results-driven, long-lasting relationship with Rocket.Chat,” said Julio Azzini, Global Head of Partnerships at Rocket.Chat.
The pandemic forced businesses around the globe to abruptly adopt the remote work environment, on a never-before-seen scale. This presented a unique opportunity for Rocket.Chat, helping to boost the company’s hyper growth - a trend that is set to continue as evidence mounts that the remote work momentum will not fade away for the foreseeable future. As an open-source business, Rocket.Chat benefits from a strong global footprint across different sectors that, combined with its recent Series A funding round , will accelerate growth and create opportunities for both Rocket.Chat and its partner ecosystem.
“The investment we made to revamp our existing (partner) program reinforces our commitment to our partners and ultimately, to our customers, to better serve them at a local level and on a global scale. Our partner ecosystem plays a crucial role in our go-to-market strategy,” shared Gabriel Engel, co-founder and CEO of Rocket.Chat. “Partners act as our service arm because they are the ones who are implementing strategic projects, scaling our apps and setting up the integrations that enable our customers to personalize and make the most of their Rocket.Chat experience.”
The new program encompasses a self-paced, scalable onboarding process that enables all key roles within a partner organization to sell and deliver projects through the Rocket.Chat partner portal. The robust capabilities of the program increase collaboration between internal teams and external providers to better manage the partner experience and overall journey while working within Rocket.Chat.
“We decided to implement the same training that we provide to our internal team to our partners. We see our partner relationships as a critical part of our company, rather than just a go-to-market channel. On top of all improvements made we have hired a very talented and competent group of professionals, now outfitted with the assets they need to ensure that we are taking our partner program -- and ultimately our partnerships -- to the next level,” added Azzini.
The new partner program operates across three tiers that are organized based on the overall capabilities and contributions of partners across all types of business models. For more information, please visit: www.Rocket.Chat/partners
About Rocket.Chat
Rocket.Chat is used by Audi, Alfa-Bank, Caixa, Daimler, HTC, Intel, Lockheed Martin, Nationwide Insurance, and other enterprises worldwide to control their communication, manage their data, and have their own collaboration platform to improve team productivity. Rocket.Chat users can switch between team chat and video or audio calls with screen sharing for more efficient teamwork. The platform’s open-source foundation empowers enterprises with complete access to the source code so that they can fully customize, extend or add new functionality to meet their unique requirements. Rocket.Chat is now installed on more than 700,000 servers, counts over 12 million users worldwide, and has an active, passionate community of over 800 developer-contributors who help Rocket.Chat’s core team of developers to constantly improve the product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005172/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom